Shares of Zydus Lifesciences fell 3% on July 19 following the classification of its Jarod injectables manufacturing facility as ‘Official Action Indicated’ (OAI) by the United States Food and Drug Administration (USFDA).
As of 1:05 PM, the shares were trading 2.63% lower at ₹1,154.45 on NSE.
The USFDA inspected the facility from April 15-23 this year and issued 10 observations. It appears that Zydus Lifesciences did not address these observations adequately, leading to the OAI classification.
This classification can result in regulatory or enforcement actions, such as warning letters, import alerts, or even product recalls, affecting the company’s operations and market performance.
